Durvalumab + Epacadostat
Phase 2Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Epstein-Barr Virus Positive
Conditions
Epstein-Barr Virus Positive, Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage III Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma, Stage IVA Nasopharyngeal Carcinoma, Stage IVB Nasopharyngeal Carcinoma
Trial Timeline
Dec 1, 2020 → Apr 1, 2024
NCT ID
NCT04231864About Durvalumab + Epacadostat
Durvalumab + Epacadostat is a phase 2 stage product being developed by AstraZeneca for Epstein-Barr Virus Positive. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04231864. Target conditions include Epstein-Barr Virus Positive, Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma.
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04231864 | Phase 2 | Withdrawn |
Competing Products
5 competing products in Epstein-Barr Virus Positive
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1189 | Moderna | Phase 1 | 0 |
| mRNA-1189 | Moderna | Phase 2 | 0 |
| mRNA-1195.1 | Moderna | Phase 1 | 0 |
| Nanatinostat in combination with valganciclovir | Viracta Therapeutics | Phase 2 | 17 |
| tabelecleucel | Atara Biotherapeutics | Pre-clinical | 16 |